Cargando…

Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and Expansion

Autologous chimeric antigen receptor engineered T-cell therapies are beginning to dramatically change the outlook for patients with several hematological malignancies. Yet methods to activate and expand these cells are limited, often pose challenges to automation, and have biological limitations imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Keskar, Vandana, Sood, Anup, Loghin, Evelina, Kovacs, Ernest, Duthie, R. Scott, Liu, Shutong, Park, Jee Hyun, Chadwick, Chrystal, Smith, Reginald, Brown, Martin, Stroncek, David F., Highfill, Steven L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566300/
https://www.ncbi.nlm.nih.gov/pubmed/32796275
http://dx.doi.org/10.1097/CJI.0000000000000329
Descripción
Sumario:Autologous chimeric antigen receptor engineered T-cell therapies are beginning to dramatically change the outlook for patients with several hematological malignancies. Yet methods to activate and expand these cells are limited, often pose challenges to automation, and have biological limitations impacting the output of the injectable dose. This study describes the development of a novel, highly flexible, soluble DNA-based T-cell activation and expansion platform which alleviates the limitations of current technologies and provides rapid T-cell activation and expansion.